NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- State
- Under way
- Phase
- Phase 3
- People
- 35 planned
- Started
- 30 Jan 2024
- Primary completion
- 4 Oct 2028
- Arms
- CSL222
- Results
- None posted
- 22 Aug 2023: Trial registered
- 30 Jan 2024: Trial started